Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

HISTORICAL FACTS: Ozempic gains first approval in canada for kidney disease and cardiovascular death risk | History Defined

Valparaiso,,In,Usa,December,13,,2023:,Ozempic,Pen,And,Box

Health Canada on Tuesday approved Novo Nordisk's (NYSE:NVO) Ozempic (semaglutide) to reduce the risk of kidney disease and cardiovascular deaths in adults with type 2 diabetes.

The approval makes Ozempic the first once-weekly treatment for type 2 diabetes that not only improves glycemic control but also lowers the risk of eGFR decline, end-stage kidney disease, and cardiovascular death.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.